These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33388277)

  • 1. Effect of Empagliflozin and Liraglutide on the Nucleotide-Binding and Oligomerization Domain-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome in a Rodent Model of Type 2 Diabetes Mellitus.
    Gordon M; Meagher P; Connelly KA
    Can J Diabetes; 2021 Aug; 45(6):553-556. PubMed ID: 33388277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats.
    Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.
    Chen H; Tran D; Yang HC; Nylander S; Birnbaum Y; Ye Y
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):443-461. PubMed ID: 32335797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
    Byrne NJ; Matsumura N; Maayah ZH; Ferdaoussi M; Takahara S; Darwesh AM; Levasseur JL; Jahng JWS; Vos D; Parajuli N; El-Kadi AOS; Braam B; Young ME; Verma S; Light PE; Sweeney G; Seubert JM; Dyck JRB
    Circ Heart Fail; 2020 Jan; 13(1):e006277. PubMed ID: 31957470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: role of oxidative stress and nitric oxide.
    Cessario J; Pierre-Louis V; Wahl J; Li Z
    Pharmacol Rep; 2021 Jun; 73(3):858-867. PubMed ID: 33555600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.
    Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J
    Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.
    Ye Y; Bajaj M; Yang HC; Perez-Polo JR; Birnbaum Y
    Cardiovasc Drugs Ther; 2017 Apr; 31(2):119-132. PubMed ID: 28447181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
    Kim SR; Lee SG; Kim SH; Kim JH; Choi E; Cho W; Rim JH; Hwang I; Lee CJ; Lee M; Oh CM; Jeon JY; Gee HY; Kim JH; Lee BW; Kang ES; Cha BS; Lee MS; Yu JW; Cho JW; Kim JS; Lee YH
    Nat Commun; 2020 May; 11(1):2127. PubMed ID: 32358544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
    Quagliariello V; De Laurentiis M; Rea D; Barbieri A; Monti MG; Carbone A; Paccone A; Altucci L; Conte M; Canale ML; Botti G; Maurea N
    Cardiovasc Diabetol; 2021 Jul; 20(1):150. PubMed ID: 34301253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3/caspase-1/GSDMD pathway in pancreatic β cells: in vitro and in vivo studies.
    Liu P; Zhang Z; Wang J; Zhang X; Yu X; Li Y
    Bioengineered; 2021 Dec; 12(2):9356-9366. PubMed ID: 34823419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination?
    Amici F; Ciarlo C; Abumusallam J; Kravitz M; Weber AR; Meister H; Li Z
    J Basic Clin Physiol Pharmacol; 2024 Jan; 35(1-2):53-60. PubMed ID: 38484469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.
    Yu X; Hao M; Liu Y; Ma X; Lin W; Xu Q; Zhou H; Shao N; Kuang H
    Eur J Pharmacol; 2019 Dec; 864():172715. PubMed ID: 31593687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation.
    Li XX; Chen ZD; Sun XJ; Yang YQ; Jin H; Liu NF
    Acta Pharmacol Sin; 2024 Apr; 45(4):751-764. PubMed ID: 38172306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model.
    Luo B; Li B; Wang W; Liu X; Liu X; Xia Y; Zhang C; Zhang Y; Zhang M; An F
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):33-43. PubMed ID: 24254031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function.
    Katogiannis K; Thymis J; Kousathana F; Pavlidis G; Korakas E; Kountouri A; Balampanis K; Prentza V; Kostelli G; Michalopoulou H; Tsilivarakis D; Lambadiari V; Ikonomidis I
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541121
    [No Abstract]   [Full Text] [Related]  

  • 17. Naringin ameliorates the high glucose-induced rat mesangial cell inflammatory reaction by modulating the NLRP3 Inflammasome.
    Chen F; Wei G; Xu J; Ma X; Wang Q
    BMC Complement Altern Med; 2018 Jun; 18(1):192. PubMed ID: 29929501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney.
    Ke Q; Shi C; Lv Y; Wang L; Luo J; Jiang L; Yang J; Zhou Y
    FASEB J; 2022 Jan; 36(1):e22078. PubMed ID: 34918381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells.
    Chen A; Chen Z; Xia Y; Lu D; Yang X; Sun A; Zou Y; Qian J; Ge J
    Biochem Biophys Res Commun; 2018 May; 499(2):267-272. PubMed ID: 29571736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rac1 GTPase Inhibition Blocked Podocyte Injury and Glomerular Sclerosis during Hyperhomocysteinemia via Suppression of Nucleotide-Binding Oligomerization Domain-Like Receptor Containing Pyrin Domain 3 Inflammasome Activation.
    Zhang Q; Conley SM; Li G; Yuan X; Li PL
    Kidney Blood Press Res; 2019; 44(4):513-532. PubMed ID: 31266025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.